Related Experiment Videos
[Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia]
Regina Lukács1, Gábor Sándor2, Miklós Resch2
1Pest Megyei Flór Ferenc Kórház Kistarcsa, Semmelweis tér 1., 2143.
Introduction:
Pathological myopia is one of the leading causes of vision loss worldwide, especially among young people of working age. Choroidal neovascularization is one of the most important cause of visual impairment in pathological myopia.
Aim:
To evaluate the efficacy of intravitreal ranibizumab for the treatment of myopic choroidal neovascularization.
Method:
In this retrospective analysis 14 eyes of 14 patients (mean age: 61 ± 17 years) with myopic choroidal neovascularization were treated with intravitreal ranibizumab as needed. Best-corrected visual acuity, thickness of choroidal neovascularization lesion and the number of injections were assessed.
Results:
The mean visual acuity changed from 55.8 ± 19.3 letters to 64.8 + 15.5 at 12 months (p = 0.0414), and 62.6 ± 16.3 during follow-up time (p = 0.2896). Mean follow-up time was 19.7 ± 23.9 months, average number of injections was 2.8 ± 2.1. Visual acuity declined in four patients despite the treatment.
Conclusions:
Intravitreal ranibizumab is an effective therapy in pathological myopia. Some patients experience deterioration of visual acuity despite of treatment. Orv. Hetil., 2017, 158(15), 579-586.